By Per Liljas
AstraZeneca has rejected Pfizer’s improved “final” bid of $92 per share, which would have made the British pharmaceutical giant worth about $116 billion, saying that the new offer “undervalues the company and its attractive prospects.”
The pursuit by American firm Pfizer’s, based on a strategy to cut its tax expenses, has been scrutinized out of fears that it would impede AstraZeneca’s drug research and cut jobs.
The debate over a potential takeover has embroiled both politicians and trade unions in the U.K., where AstraZeneca currently employes 6,700 people. AstraZeneca’s shares fell over 13% in early trading after the rejection of the offer.
[BBC]
More Must-Reads From TIME
- Jane Fonda Champions Climate Action for Every Generation
- Biden’s Campaign Is In Trouble. Will the Turnaround Plan Work?
- Why We're Spending So Much Money Now
- The Financial Influencers Women Actually Want to Listen To
- Breaker Sunny Choi Is Heading to Paris
- Why TV Can’t Stop Making Silly Shows About Lady Journalists
- The Case for Wearing Shoes in the House
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time
Contact us at letters@time.com